Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $17.0 million.

  • Gossamer Bio's Cash from Investing Activities rose 16359.42% to $17.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.4 million, marking a year-over-year increase of 45379.03%. This contributed to the annual value of $29.0 million for FY2024, which is 12615.39% up from last year.
  • As of Q3 2025, Gossamer Bio's Cash from Investing Activities stood at $17.0 million, which was up 16359.42% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Cash from Investing Activities ranged from a high of $61.7 million in Q1 2024 and a low of -$118.3 million during Q3 2023
  • Its 4-year average for Cash from Investing Activities is $14666.7, with a median of $8.5 million in 2022.
  • The largest annual percentage gain for Gossamer Bio's Cash from Investing Activities in the last 5 years was 60709.7% (2024), contrasted with its biggest fall of 55695.73% (2024).
  • Gossamer Bio's Cash from Investing Activities (Quarter) stood at $8.5 million in 2022, then tumbled by 269.73% to -$14.4 million in 2023, then surged by 470.43% to $53.2 million in 2024, then tumbled by 68.03% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q3 2025, $44.1 million for Q2 2025, and $22.1 million during Q1 2025.